BridgeBio Pharma vs Summit Therapeutics

BridgeBio Pharma (BBIO), health care, and Summit Therapeutics (SMMT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

BridgeBio Pharma is worth $15B on the stock market and Summit Therapeutics $8.5B: BridgeBio Pharma is valued at 75% more. Over the past year BridgeBio Pharma's share price has moved +17.9% and Summit Therapeutics's -29.7%.

Key facts

BridgeBio Pharma market value
$15B
Summit Therapeutics market value
$8.5B
BridgeBio Pharma revenue
$502.1MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

BridgeBio Pharma vs Summit Therapeutics: every measure side by side
Measure BridgeBio Pharma Summit Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$15Bhigher$8.5Blower
Revenue$502.1M—
Earnings-$732.9Mhigher-$1.1Blower
Employees1,081higher265lower
Total assets$936Mhigher$751.2Mlower
Valuation
P/E——
P/S29.8—
P/B—15.1
Dividend yield0.00%0.00%
Profitability
Operating margin-104%—
Balance sheet
Net assets-$2.1Blower$658.9Mhigher
Total liabilities$3Bhigher$92.3Mlower
Total debt$2B—
Cash on hand$570.1Mhigher$225.3Mlower
Price change
Today-0.72%higher-9.73%lower
1 year+17.9%higher-29.7%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Summit Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns BBIO · Who owns SMMT

Further comparisons

Learn

Questions and answers

Which is bigger, BridgeBio Pharma or Summit Therapeutics?

By market value, BridgeBio Pharma is the larger: $15B against $8.5B for Summit Therapeutics.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both BridgeBio Pharma and Summit Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 8 hold BridgeBio Pharma and 1 holds Summit Therapeutics.

Cite this page

Funkfolio, “BridgeBio Pharma vs Summit Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/bbio-vs-smmt

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.